OBSERVATION VS INTENSIVE CHEMOTHERAPY FOR INDOLENT LYMPHOMA

这项研究是12年前设计的，目的是 比较两种方案的疗效和长期存活率 对以前未接受治疗的人采取不同的治疗方法 惰性淋巴瘤患者：观察或延迟治疗 (观察和等待)与初始强化联合化疗 使用ProMACE/MOPP柔韧疗法来完成缓解， 然后进行固定性改良全结节放疗。到目前为止 在无病存活率或总体上没有显著差异 存活率，尽管完全应答率存在差异 在两个随机组之间，76%的患者 随机接受强化治疗，获得完全缓解 相比之下，经过一段时间的治疗后，接受治疗的患者的CR率为37% 观察。中位随访时间为十年。续 随访可能会显示对部分患者有好处。这项研究 已经对进一步的病人收益关闭了。更长的随访时间是 有必要确定两者之间是否存在存活率差异 不同的治疗方法。被随机分配到WW的患者 ARM将继续被交叉，并按照协议进行治疗。 自上一份报告以来，还没有出现跨界。

"This study was designed twelve years ago to compare the efficacy and the long-term survival of two very different therapeutic approaches towards previously untreated patients with indolent lymphoma: observation or delayed therapy (watch and wait) vs. initial intensive combination chemotherapy with ProMACE/MOPP flexitherapy to complete remission, followed by consolidative modified total nodal irradiation. To date there are no significant differences in disease-free survival or overall survival, although there are differences in complete response rates between the two randomized groups with 76% of patients randomized to intensive therapy achieving a complete response compared to a CR rate of 37% in those treated after a period of observation. The median follow-up time is ten years. Continued follow-up may show a benefit for a subset of patients. The study has been closed to further patient accrual. Longer follow-up is necessary to determine if there is a survival difference between the different treatment approaches. Patients randomized to the WW arm will continue to be crossed over and treated per protocol. There have been no crossovers since the last report."